Jazz Pharmaceuticals-Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics

Core Insights - Jazz Pharmaceuticals reported revenue of $1.09 billion for the quarter ended December 2024, reflecting a year-over-year increase of 7.5% and an EPS of$ 6.60, up from $5.02 in the same quarter last year, surpassing both revenue and EPS consensus estimates [1] Revenue Performance - Product sales netted$ 1.03 billion, exceeding the average analyst estimate of $995.17 million, with a year-over-year change of +6% [4] - Oncology product Defitelio/defibrotide generated$ 57.65 million, surpassing the nine-analyst average estimate of $46.52 million, marking a +12.9% year-over-year change [4] - Neuroscience product Oxybate (Xywav) achieved$ 400.96 million, exceeding the average estimate of $393.28 million, with a +19% year-over-year change [4] - Neuroscience product Epidiolex/Epidyolex reported$ 275.05 million, compared to the average estimate of $264.59 million, reflecting a +14.3% year-over-year change [4] - Neuroscience product Sativex generated$ 5.17 million, slightly below the average estimate of $6.58 million, with a +0.7% year-over-year change [4] - Total revenues from Neuroscience reached$ 730.47 million, exceeding the average estimate of $714.23 million, with a +5.9% year-over-year change [4] - Total revenues from Oncology amounted to$ 291.76 million, surpassing the average estimate of $276.22 million, with a +6.6% year-over-year change [4] - Rylaze generated$ 101.49 million, slightly below the average estimate of $99.81 million, with a -0.3% year-over-year change [4] - Vyxeos achieved$ 53.25 million, exceeding the average estimate of $42.05 million, with a +13.5% year-over-year change [4] - Zepzelca reported$ 78.33 million, below the average estimate of $91.31 million, with a +5.8% year-over-year change [4] - Other revenues totaled$ 2.97 million, below the average estimate of $3.84 million, reflecting a -27.3% year-over-year change [4] Stock Performance - Jazz Pharmaceuticals' shares returned +9.9% over the past month, contrasting with the Zacks S&P 500 composite's -1.8% change, indicating strong relative performance [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]